Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Harmony Biosciences Holdings, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Harmony Biosciences Holdings, Inc. (HRMY) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. (“Harmony” or “the Company”) (NASDAQ: HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Harmony has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On February 19, 2025, Harmony announced that it had received “a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH).” The Company added, “the primary outcome for EDS between pitolisant and placebo did not reach statistical significance in the randomized withdrawal phase of the Phase 3 INTUNE Study.” Following this news, Harmony stock dropped by 9.64% on the same day.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Harmony securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
How Did Harmony Biosciences Holdings, Inc. (HRMY) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”